Osteoporosis screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
[[ | Today, risk of [[fracture]] due to [[osteoporosis]] is threatening one out of two [[postmenopausal]] women and also one out of five older men. The 10-year risk for any [[osteoporosis]]-related [[fractures]] in 65-year-old white woman with no other risk factor is 9.3%. Upon the guidelines of [[United states preventive services task force recommendations scheme|USPSTF]], all women ≥ 65 years old along with women < 65 years old with high risk of [[fracture]] are target of screening for [[osteoporosis]]; but there is not any recommendation to screen men for the [[disease]]. There are two major methods, that is suggested to use for screening [[osteoporosis]]: [[Dual energy X-ray absorptiometry|dual energy x-ray absorptiometry]] (DXA) of both [[hip]] and [[lumbar spine]] [[bones]], and quantitative [[ultrasonography]] of the [[calcaneus]]. | ||
==Screening== | ==Screening== | ||
=== Risk assessment === | === Risk assessment === | ||
* Today, risk of fracture due to osteoporosis is threatening one out of two postmenopausal women and also one out of five older men. Leading ethnicity involved in osteoporosis is white. The rate of osteoporosis is higher in elderly. The 10-year risk for any osteoporosis-related fractures in 65-year-old white woman with no other risk factor is 9.3%. The 10-year probability of hip fracture can be estimated by the [http://www.shef.ac.uk/FRAX/ FRAX tool] based on the presence or absence of clinical risk factors in addition to the bone mineral density (BMD) at the femoral neck. | * Today, risk of [[fracture]] due to [[osteoporosis]] is threatening one out of two [[postmenopausal]] women and also one out of five older men. Leading ethnicity involved in osteoporosis is white. The rate of [[osteoporosis]] is higher in elderly. The 10-year risk for any [[osteoporosis]]-related [[fractures]] in 65-year-old white woman with no other risk factor is 9.3%. The 10-year probability of [[hip]] [[fracture]] can be estimated by the [http://www.shef.ac.uk/FRAX/ FRAX tool] based on the presence or absence of clinical risk factors in addition to the [[Bone mineral density|bone mineral density (BMD)]] at the [[femoral neck]]. | ||
=== Screening criteria === | === Screening criteria === | ||
* The US Preventive Services Task Force (USPSTF) divides the population to three groups, categorize their need to be screened for osteoporosis; they include: | * The [[US Preventive Services Task Force|US Preventive Services Task Force (USPSTF)]] divides the population to three groups, categorize their need to be screened for [[osteoporosis]]; they include: | ||
# Women of 65 years and older, without any fracture history or pathological reason for osteoporosis | # Women of 65 years and older, without any [[fracture]] history or pathological reason for [[osteoporosis]] | ||
# Women of less than 65 years, with 10-year fracture risk of not less than a 65-year-old white woman (who has not any other risk factor) | # Women of less than 65 years, with 10-year [[fracture]] risk of not less than a 65-year-old white woman (who has not any other risk factor) | ||
# Men with no osteoporosis history | # Men with no [[osteoporosis]] history | ||
* Upon the guidelines of USPSTF, the former two groups (women) are target of screening for osteoporosis; but there is not any recommendation to screen the third group (men) for the disease.<ref name="pmid21242341">{{cite journal| author=U.S. Preventive Services Task Force| title=Screening for osteoporosis: U.S. preventive services task force recommendation statement. | journal=Ann Intern Med | year= 2011 | volume= 154 | issue= 5 | pages= 356-64 | pmid=21242341 | doi=10.7326/0003-4819-154-5-201103010-00307 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21242341 }} </ref> | * Upon the guidelines of [[United states preventive services task force recommendations scheme|USPSTF]], the former two groups (women) are target of screening for [[osteoporosis]]; but there is not any recommendation to screen the third group (men) for the disease.<ref name="pmid21242341">{{cite journal| author=U.S. Preventive Services Task Force| title=Screening for osteoporosis: U.S. preventive services task force recommendation statement. | journal=Ann Intern Med | year= 2011 | volume= 154 | issue= 5 | pages= 356-64 | pmid=21242341 | doi=10.7326/0003-4819-154-5-201103010-00307 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21242341 }} </ref> | ||
* Prior USPSTF recommendations from 2002 were include: | * Prior [[USPSTF]] recommendations from 2002 were include: | ||
** All women of 65 and older should be screened by bone marrow densitometry.<ref name="pmid12230355">{{cite journal |author=U.S. Preventive Services Task Force |title=Screening for osteoporosis in postmenopausal women: recommendations and rationale |journal=Ann. Intern. Med. |volume=137 |issue=6 |pages=526-8|year=2002 |pmid=12230355 |doi=}}</ref> | ** All women of 65 and older should be screened by [[Bone mineral density|bone marrow densitometry]].<ref name="pmid12230355">{{cite journal |author=U.S. Preventive Services Task Force |title=Screening for osteoporosis in postmenopausal women: recommendations and rationale |journal=Ann. Intern. Med. |volume=137 |issue=6 |pages=526-8|year=2002 |pmid=12230355 |doi=}}</ref> | ||
** The USPSTF recommends screening women aged 60-64 years old, who are at increased risk of fracture. The most significant risk factor for indicating an increased probability of having osteoporosis is lower body weight (< 70 kg). | ** The [[United states preventive services task force recommendations scheme|USPSTF]] recommends screening women aged 60-64 years old, who are at increased risk of [[fracture]]. The most significant risk factor for indicating an increased probability of having [[osteoporosis]] is lower [[body weight]] (< 70 kg). | ||
** Clinical prediction rules are available to guide selection of women for screening. The [http://osteoed.org/tools.php?type=orai Osteoporosis Risk Assessment Instrument (ORAI)] may be the most [[sensitivity (tests)|sensitive]] strategy.<ref name="pmid17552058">{{cite journal |author=Martínez-Aguilà D, Gómez-Vaquero C, Rozadilla A, Romera M, Narváez J, Nolla JM |title=Decision rules for selecting women for bone mineral density testing: application in postmenopausal women referred to a bone densitometry unit |journal=J. Rheumatol. |volume=34 |issue=6|pages=1307-12 |year=2007 |pmid=17552058 |doi=}}</ref> | ** Clinical prediction rules are available to guide selection of women for screening. The [http://osteoed.org/tools.php?type=orai Osteoporosis Risk Assessment Instrument (ORAI)] may be the most [[sensitivity (tests)|sensitive]] strategy.<ref name="pmid17552058">{{cite journal |author=Martínez-Aguilà D, Gómez-Vaquero C, Rozadilla A, Romera M, Narváez J, Nolla JM |title=Decision rules for selecting women for bone mineral density testing: application in postmenopausal women referred to a bone densitometry unit |journal=J. Rheumatol. |volume=34 |issue=6|pages=1307-12 |year=2007 |pmid=17552058 |doi=}}</ref> | ||
** Regarding the screening process for men, a cost-analysis study suggests that screening may be "cost-effective for men with a self-reported prior fracture beginning at age 65 years, and for men 80 years and older with no prior fracture".<ref name="pmid17684185">{{cite journal |author=Schousboe JT, Taylor BC, Fink HA, ''et al'' |title=Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men |journal=JAMA |volume=298 |issue=6 |pages=629-37 |year=2007 |pmid=17684185|doi=10.1001/jama.298.6.629}}</ref> | ** Regarding the [[screening]] process for men, a cost-analysis study suggests that [[screening]] may be "cost-effective for men with a self-reported prior [[fracture]] beginning at age 65 years, and for men 80 years and older with no prior [[fracture]]".<ref name="pmid17684185">{{cite journal |author=Schousboe JT, Taylor BC, Fink HA, ''et al'' |title=Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men |journal=JAMA |volume=298 |issue=6 |pages=629-37 |year=2007 |pmid=17684185|doi=10.1001/jama.298.6.629}}</ref> | ||
=== Screening tool === | === Screening tool === | ||
* There are two major methods, that is suggested to use for screening osteoporosis; they include: | * There are two major methods, that is suggested to use for screening [[osteoporosis]]; they include: | ||
# Dual energy x-ray absorptiometry (DXA) of both hip and lumbar spine bones | # [[Dual energy X-ray absorptiometry|Dual energy x-ray absorptiometry (DXA)]] of both [[hip]] and [[lumbar spine]] [[bones]] | ||
# Quantitative ultrasonography of the calcaneus | # Quantitative [[ultrasonography]] of the [[calcaneus]] | ||
* Although quantitative ultrasonography has lower price, more portability, lower ionizing radiation exposure for patients, and otherwise the same power of fracture prediction (in femoral neck, hip, and spine) comparing with DXA method, current diagnostic and treatment criteria rely on DXA of the hip and lumbar spine. | * Although quantitative [[ultrasonography]] has lower price, more portability, lower [[ionizing radiation]] exposure for patients, and otherwise the same power of [[fracture]] prediction (in [[femoral neck]], [[hip]], and [[spine]]) comparing with DXA method, current diagnostic and treatment criteria rely on DXA of the [[hip]] and [[lumbar spine]]. | ||
=== Screening protocol === | === Screening protocol === | ||
* After an initial screening [[bone mineral density | * After an initial screening [[bone mineral density|bone mineral density (BMD)]], optimal intervals to repeat the test may include the followings: | ||
** 15 years for women with normal bone density or mild osteopenia: T-score of greater than −1.50 | ** 15 years for women with normal [[bone density]] or mild [[osteopenia]]: T-score of greater than −1.50 | ||
** 5 years for women with moderate osteopenia: T-score of −1.50 to −1.99 | ** 5 years for women with moderate [[osteopenia]]: T-score of −1.50 to −1.99 | ||
** 1 year for women with advanced osteopenia: T-score of −2.00 to −2.49 <ref name="pmid22256806">{{cite journal |vauthors=Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui LY, Ransohoff DF, Cauley JA, Ensrud KE |title=Bone-density testing interval and transition to osteoporosis in older women |journal=N. Engl. J. Med. |volume=366 |issue=3 |pages=225–33 |year=2012 |pmid=22256806 |pmc=3285114 |doi=10.1056/NEJMoa1107142 |url=}}</ref> | ** 1 year for women with advanced [[osteopenia]]: T-score of −2.00 to −2.49 <ref name="pmid22256806">{{cite journal |vauthors=Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui LY, Ransohoff DF, Cauley JA, Ensrud KE |title=Bone-density testing interval and transition to osteoporosis in older women |journal=N. Engl. J. Med. |volume=366 |issue=3 |pages=225–33 |year=2012 |pmid=22256806 |pmc=3285114 |doi=10.1056/NEJMoa1107142 |url=}}</ref> | ||
=== Osteoporosis Screening Recommendations of Other Organizations === | === Osteoporosis Screening Recommendations of Other Organizations === | ||
| Line 49: | Line 49: | ||
|- | |- | ||
! National Osteoporosis Foundation (NOF) <ref name="pmid25182228">{{cite journal| author=Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S et al.| title=Clinician's Guide to Prevention and Treatment of Osteoporosis. | journal=Osteoporos Int | year= 2014 | volume= 25 | issue= 10 | pages= 2359-81 | pmid=25182228 | doi=10.1007/s00198-014-2794-2 | pmc=4176573 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25182228 }}</ref> | ! [[National Osteoporosis Foundation|National Osteoporosis Foundation (NOF)]] <ref name="pmid25182228">{{cite journal| author=Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S et al.| title=Clinician's Guide to Prevention and Treatment of Osteoporosis. | journal=Osteoporos Int | year= 2014 | volume= 25 | issue= 10 | pages= 2359-81 | pmid=25182228 | doi=10.1007/s00198-014-2794-2 | pmc=4176573 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25182228 }}</ref> | ||
| BMD testing for: | | [[Bone mineral density|BMD]] testing for: | ||
* All ≥ 65 years old | * All ≥ 65 years old | ||
* Postmenopausal <65 years old, based on risk factor profile | * [[Postmenopausal]] <65 years old, based on risk factor profile | ||
| BMD testing for: | | [[Bone mineral density|BMD]] testing for: | ||
* All men ≥70 years old | * All men ≥70 years old | ||
* Men aged 50-69 years old, based on risk factor profile | * Men aged 50-69 years old, based on risk factor profile | ||
| Line 61: | Line 61: | ||
|- | |- | ||
! World Health Organization (WHO) <ref name="urlwww.euro.who.int">{{cite web |url=http://www.euro.who.int/document/e88668.pdf |title=www.euro.who.int |format= |work= |accessdate=}}</ref> | ! [[World Health Organization|World Health Organization (WHO)]] <ref name="urlwww.euro.who.int">{{cite web |url=http://www.euro.who.int/document/e88668.pdf |title=www.euro.who.int |format= |work= |accessdate=}}</ref> | ||
| Indirect records suggest screening women ≥65 years old, while no direct record suggests using BMD testing for holistic screening programs | | Indirect records suggest screening women ≥65 years old, while no direct record suggests using BMD testing for holistic screening programs | ||
| Line 69: | Line 69: | ||
|- | |- | ||
! American College of Physicians <ref name="pmid18458281">{{cite journal |vauthors=Qaseem A, Snow V, Shekelle P, Hopkins R, Forciea MA, Owens DK |title=Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians |journal=Ann. Intern. Med. |volume=148 |issue=9 |pages=680–4 |year=2008 |pmid=18458281 |doi= |url=}}</ref> | ! [[American College of Physicians]] <ref name="pmid18458281">{{cite journal |vauthors=Qaseem A, Snow V, Shekelle P, Hopkins R, Forciea MA, Owens DK |title=Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians |journal=Ann. Intern. Med. |volume=148 |issue=9 |pages=680–4 |year=2008 |pmid=18458281 |doi= |url=}}</ref> | ||
| - | | - | ||
| Clinicians should investigate older men for osteoporosis risk factors; use DXA to screen men with increased risk, maybe candidates of drug therapy for osteoporosis | | Clinicians should investigate older men for [[osteoporosis]] risk factors; use [[Dual energy X-ray absorptiometry|DXA]] to screen men with increased risk, maybe candidates of drug therapy for [[osteoporosis]] | ||
|- | |- | ||
| Line 79: | Line 79: | ||
! American Congress of Obstetricians and Gynecologists (ACOG) <ref name="pmid22914492">{{cite journal |vauthors= |title=ACOG Practice Bulletin N. 129. Osteoporosis |journal=Obstet Gynecol |volume=120 |issue=3 |pages=718–34 |year=2012 |pmid=22914492 |doi=10.1097/AOG.0b013e31826dc446 |url=}}</ref> | ! American Congress of Obstetricians and Gynecologists (ACOG) <ref name="pmid22914492">{{cite journal |vauthors= |title=ACOG Practice Bulletin N. 129. Osteoporosis |journal=Obstet Gynecol |volume=120 |issue=3 |pages=718–34 |year=2012 |pmid=22914492 |doi=10.1097/AOG.0b013e31826dc446 |url=}}</ref> | ||
| BMD testing for: | | [[Bone mineral density|BMD]] testing for: | ||
* All ≥65 yearcs old | * All ≥65 yearcs old | ||
* Postmenopausal <65 years old, with 1 or more risk factors | * [[Postmenopausal]] <65 years old, with 1 or more risk factors | ||
| - | | - | ||
Revision as of 16:57, 3 August 2017
|
Osteoporosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Medical Therapy |
|
Case Studies |
|
Osteoporosis screening On the Web |
|
American Roentgen Ray Society Images of Osteoporosis screening |
|
Risk calculators and risk factors for Osteoporosis screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2], Raviteja Guddeti, M.B.B.S.[3]
Overview
Today, risk of fracture due to osteoporosis is threatening one out of two postmenopausal women and also one out of five older men. The 10-year risk for any osteoporosis-related fractures in 65-year-old white woman with no other risk factor is 9.3%. Upon the guidelines of USPSTF, all women ≥ 65 years old along with women < 65 years old with high risk of fracture are target of screening for osteoporosis; but there is not any recommendation to screen men for the disease. There are two major methods, that is suggested to use for screening osteoporosis: dual energy x-ray absorptiometry (DXA) of both hip and lumbar spine bones, and quantitative ultrasonography of the calcaneus.
Screening
Risk assessment
- Today, risk of fracture due to osteoporosis is threatening one out of two postmenopausal women and also one out of five older men. Leading ethnicity involved in osteoporosis is white. The rate of osteoporosis is higher in elderly. The 10-year risk for any osteoporosis-related fractures in 65-year-old white woman with no other risk factor is 9.3%. The 10-year probability of hip fracture can be estimated by the FRAX tool based on the presence or absence of clinical risk factors in addition to the bone mineral density (BMD) at the femoral neck.
Screening criteria
- The US Preventive Services Task Force (USPSTF) divides the population to three groups, categorize their need to be screened for osteoporosis; they include:
- Women of 65 years and older, without any fracture history or pathological reason for osteoporosis
- Women of less than 65 years, with 10-year fracture risk of not less than a 65-year-old white woman (who has not any other risk factor)
- Men with no osteoporosis history
- Upon the guidelines of USPSTF, the former two groups (women) are target of screening for osteoporosis; but there is not any recommendation to screen the third group (men) for the disease.[1]
- Prior USPSTF recommendations from 2002 were include:
- All women of 65 and older should be screened by bone marrow densitometry.[2]
- The USPSTF recommends screening women aged 60-64 years old, who are at increased risk of fracture. The most significant risk factor for indicating an increased probability of having osteoporosis is lower body weight (< 70 kg).
- Clinical prediction rules are available to guide selection of women for screening. The Osteoporosis Risk Assessment Instrument (ORAI) may be the most sensitive strategy.[3]
- Regarding the screening process for men, a cost-analysis study suggests that screening may be "cost-effective for men with a self-reported prior fracture beginning at age 65 years, and for men 80 years and older with no prior fracture".[4]
Screening tool
- There are two major methods, that is suggested to use for screening osteoporosis; they include:
- Dual energy x-ray absorptiometry (DXA) of both hip and lumbar spine bones
- Quantitative ultrasonography of the calcaneus
- Although quantitative ultrasonography has lower price, more portability, lower ionizing radiation exposure for patients, and otherwise the same power of fracture prediction (in femoral neck, hip, and spine) comparing with DXA method, current diagnostic and treatment criteria rely on DXA of the hip and lumbar spine.
Screening protocol
- After an initial screening bone mineral density (BMD), optimal intervals to repeat the test may include the followings:
- 15 years for women with normal bone density or mild osteopenia: T-score of greater than −1.50
- 5 years for women with moderate osteopenia: T-score of −1.50 to −1.99
- 1 year for women with advanced osteopenia: T-score of −2.00 to −2.49 [5]
Osteoporosis Screening Recommendations of Other Organizations
| Organizations | Women | Men |
|---|---|---|
| National Osteoporosis Foundation (NOF) [6] | BMD testing for:
|
BMD testing for:
|
| World Health Organization (WHO) [7] | Indirect records suggest screening women ≥65 years old, while no direct record suggests using BMD testing for holistic screening programs | - |
| American College of Physicians [8] | - | Clinicians should investigate older men for osteoporosis risk factors; use DXA to screen men with increased risk, maybe candidates of drug therapy for osteoporosis |
| American Congress of Obstetricians and Gynecologists (ACOG) [9] | BMD testing for:
|
- |
References
- ↑ U.S. Preventive Services Task Force (2011). "Screening for osteoporosis: U.S. preventive services task force recommendation statement". Ann Intern Med. 154 (5): 356–64. doi:10.7326/0003-4819-154-5-201103010-00307. PMID 21242341.
- ↑ U.S. Preventive Services Task Force (2002). "Screening for osteoporosis in postmenopausal women: recommendations and rationale". Ann. Intern. Med. 137 (6): 526–8. PMID 12230355.
- ↑ Martínez-Aguilà D, Gómez-Vaquero C, Rozadilla A, Romera M, Narváez J, Nolla JM (2007). "Decision rules for selecting women for bone mineral density testing: application in postmenopausal women referred to a bone densitometry unit". J. Rheumatol. 34 (6): 1307–12. PMID 17552058.
- ↑ Schousboe JT, Taylor BC, Fink HA; et al. (2007). "Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men". JAMA. 298 (6): 629–37. doi:10.1001/jama.298.6.629. PMID 17684185.
- ↑ Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui LY, Ransohoff DF, Cauley JA, Ensrud KE (2012). "Bone-density testing interval and transition to osteoporosis in older women". N. Engl. J. Med. 366 (3): 225–33. doi:10.1056/NEJMoa1107142. PMC 3285114. PMID 22256806.
- ↑ Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S; et al. (2014). "Clinician's Guide to Prevention and Treatment of Osteoporosis". Osteoporos Int. 25 (10): 2359–81. doi:10.1007/s00198-014-2794-2. PMC 4176573. PMID 25182228.
- ↑ "www.euro.who.int" (PDF).
- ↑ Qaseem A, Snow V, Shekelle P, Hopkins R, Forciea MA, Owens DK (2008). "Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians". Ann. Intern. Med. 148 (9): 680–4. PMID 18458281.
- ↑ "ACOG Practice Bulletin N. 129. Osteoporosis". Obstet Gynecol. 120 (3): 718–34. 2012. doi:10.1097/AOG.0b013e31826dc446. PMID 22914492.